Communiqués Cyclacel Pharmaceuticals, Inc.

Actions

CYCC

US23254L8019

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
1,62 ^USD	-4,71%		-7,43%	-39,33%

26/06	Mise à jour sectorielle : Les actions du secteur de la santé en baisse en fin d'après-midi	MT
26/06	Mise à jour sectorielle : Les actions du secteur de la santé en baisse dans l'après-midi	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Cyclacel Pharmaceuticals : A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma	03/06	PU
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results	09/05	AQ
Cyclacel Pharmaceuticals : April 2024 Corporate Presentation	02/04	PU
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	20/03	AQ
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be presented at the American Association for Cancer Research Annual Meeting 2024	08/03	AQ
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit	07/03	AQ
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO and Investor Conference	21/02	AQ
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer	31/01	AQ
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024	03/01	AQ
Cyclacel Receives Notification of Deficiency from Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q	29/11	AQ
Cyclacel Pharmaceuticals : September 2023 Corporate Presentation	15/09/23	PU
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update	10/08/23	AQ
CYCLACEL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	14/06/23	AQ
Cyclacel Pharmaceuticals : March 2023 Corporate Presentation	13/06/23	PU
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update	12/05/23	AQ
CYCLACEL PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	11/05/23	AQ
CYCLACEL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	04/05/23	AQ
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit	04/05/23	AQ
Cyclacel Pharmaceuticals : March 2023 Corporate Presentation	28/03/23	PU
CYCLACEL PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)	13/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cyclacel Pharmaceuticals, Inc.

Actions

CYCC

US23254L8019

Communiqués

Filtres